Comparison of prognostic factors, cellular density, and clinical outcomea
| Age (yr) | MMSE | KPS | Days to Tx | Months to F/U MRI | No. Tx to F/U MRI | Change CE Volume | Months to Progression | Months to Death | |
|---|---|---|---|---|---|---|---|---|---|
| Low ADC | 56.7 (15.6) | 25.2 (6.11) | 62.2 (6.67) | 13.8 (14.6) | 8.3 (14) | 2.00 (1.41) | 2.50 (2.88) | 9.4 (12.0) | 15.8 (9.87) |
| High ADC | 59.3 (11.3) | 25.7 (4.50) | 66.7 (5.00) | 13.4 (11.7) | 4.0 (8.0) | 1.70 (0.70) | 3.92 (2.39) | 30.0 (18.0) | 30.9 (17.0) |
| Pvalue | .70 | .83 | .13 | .94 | .39 | .53 | 0.37 | <.01 | .03 |
Note:—MMSE indicates pretherapeutic Mini-Mental State Examination score; KPS, Karnovsky performance status; Days to Tx, mean number of days between initial diagnosis by MR imaging and initiation of methotrexate-based chemotherapy; Months to F/U MRI, mean number of months between pre- and intratherapeutic MR imaging; No. Tx to F/U MRI, mean number of methotrexate treatments between pre- and intratherapeutic MR imaging; Change CE, difference in enhancing volume between pre-and posttherapeutic imaging series; Months to Progression, mean number of months to progression based on MR imaging if event occurred; Months to Death, mean number of months to death if event occurred.
a All data are presented as mean (± SD). Patients are stratified based on median 25th percentile value.